Wednesday, June 10, 2026

pharma Β· Asthma Β· Multiple Sclerosis Β· TEVA

Teva Pharma

Teva Pharma clinical programs β€” 148 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

10 Dornierstr., Ulm, Donau, 89079, DE, TEL AVIV HQ
126 Employees
Public company Type
TEVA Β· NYSE Ticker
Company details
Intelligence Β· Clinical Programs

Teva Pharma projects

148 ClinicalTrials.gov programs sponsored by Teva Pharma.

Teva Pharma has 148 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

Page 4 of 4
  1. pagoclone

    Teva Pharma GmbH

    Stuttering

    phase 3 small molecule completed

    1 trial
  2. rasagiline

    Teva Pharma GmbH

    Restless Legs Syndrome

    phase 3 small molecule terminated

    1 trial
  3. reslizumab

    Teva Pharma GmbH

    Eosinophilic Esophagitis

    phase 3 small molecule completed

    2 trials
  4. reslizumab

    Teva Pharma GmbH

    Eosinophils, Asthma

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does Teva Pharma have?

148 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.